Literature DB >> 22614910

Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.

Ulrich Schraermeyer1, Sylvie Julien.   

Abstract

BACKGROUND: In this study, the effect of intravitreal injection of bevacizumab on choroidal blood vessels was examined in primate eyes.
METHODS: Four Cynomolgus monkeys received an intravitreal injection of 1.25 mg bevacizumab. The eyes were enucleated on days 1, 4, 7 and 14. For each animal, one eye was embedded in paraffin whereas the other eye was embedded for electron microscopy. Seven untreated or PBS (phosphate buffered saline)-injected monkeys were used as controls.
RESULTS: Thrombotic microangiopathy was found in the choriocapillaris and choroidal vessels of all eight injected eyes. Acute microangiopathy was characterized ultrastructurally as swelling of the endothelium, loss of fenestrations and complete collapse of the capillaries, and was commonly observed in bevacizumab-treated eyes. Quantitative analysis showed reduction of the lumina of the choriocapillaris in the eyes of three of the monkeys. Bevacizumab was frequently localized inside the blood vessels, often filling the entire breadth of the vessels, and formed clusters with blood cells. Death of photoreceptors occurred in two monkeys.
CONCLUSIONS: This study indicate that intravitreal injection of bevacizumab in monkeys induces activation of platelets, degranulation of thrombocytes and neutrophils, formation of immune complexes, thrombotic microangiopathy and alteration of the blood flow in choroidal vessels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614910     DOI: 10.1007/s00417-012-2055-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration.

Authors:  Hamid Hosseini; Mehrzad Lotfi; Mina Heidari Esfahani; Nariman Nassiri; Mohammad Reza Khalili; Mohammad Reza Razeghinejad; Kouros Nouri-Mahdavi
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

Review 2.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

3.  The identification of platelets and platelet antigens in histological sections.

Authors:  K C Carstairs
Journal:  J Pathol Bacteriol       Date:  1965-07

4.  Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation.

Authors:  H G Blaauwgeers; G M Holtkamp; H Rutten; A N Witmer; P Koolwijk; T A Partanen; K Alitalo; M E Kroon; A Kijlstra; V W van Hinsbergh; R O Schlingemann
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.

Authors:  Angela M Carneiro; Daniel Barthelmes; Manuel S Falcão; Luis S Mendonça; Sofia L Fonseca; Rita M Gonçalves; Fernando Faria-Correia; Fernando M Falcão-Reis
Journal:  Ophthalmologica       Date:  2011-02-18       Impact factor: 3.250

6.  Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes.

Authors:  Doan C Nguyen; Franco Scinicariello; Roberta Attanasio
Journal:  Immunogenetics       Date:  2011-02-16       Impact factor: 2.846

7.  Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.

Authors:  T Meyer; L Robles-Carrillo; T Robson; F Langer; H Desai; M Davila; M Amaya; J L Francis; A Amirkhosravi
Journal:  J Thromb Haemost       Date:  2008-10-30       Impact factor: 5.824

Review 8.  Bevacizumab (Avastin) for the treatment of ocular disease.

Authors:  Jonathan B Gunther; Michael M Altaweel
Journal:  Surv Ophthalmol       Date:  2009 May-Jun       Impact factor: 6.048

9.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

10.  Retinal artery occlusion following intravitreal anti-VEGF therapy.

Authors:  Therese von Hanno; Bettina Kinge; Kristian Fossen
Journal:  Acta Ophthalmol       Date:  2009-04-08       Impact factor: 3.761

View more
  14 in total

1.  The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.

Authors:  Maximilian Ludinsky; Sarah Christner; Nan Su; Tatjana Taubitz; Alexander Tschulakow; Antje Biesemeier; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-22       Impact factor: 3.117

Review 2.  Glycobiology of ocular angiogenesis.

Authors:  Anna I Markowska; Zhiyi Cao; Noorjahan Panjwani
Journal:  Glycobiology       Date:  2014-08-08       Impact factor: 4.313

3.  Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.

Authors:  Waheeda Rahman; Fred Kuanfu Chen; Jonathan Yeoh; Lyndon da Cruz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-17       Impact factor: 3.117

4.  A new kind of labyrinth-like capillary is responsible for leakage from human choroidal neovascular endothelium, as investigated by high-resolution electron microscopy.

Authors:  Ulrich Schraermeyer; Sylvie Julien; Antje Biesemeier; Karl Ulrich Bartz-Schmidt; Hartwig Wolburg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-22       Impact factor: 3.117

5.  Effects of intravitreally injected Fc fragment on rat eyes.

Authors:  Tatjana Taubitz; Laura-Pia Steinbrenner; Alexander V Tschulakow; Antje Biesemeier; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-17       Impact factor: 3.117

6.  Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.

Authors:  Wendy Chen; Gil Binenbaum; Karen Karp; Agnieshka Baumritter; Denise J Pearson; Albert M Maguire; Graham E Quinn
Journal:  J AAPOS       Date:  2014-08-01       Impact factor: 1.220

7.  Towards a quantitative OCT image analysis.

Authors:  Marina Garcia Garrido; Susanne C Beck; Regine Mühlfriedel; Sylvie Julien; Ulrich Schraermeyer; Mathias W Seeliger
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

8.  Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

Authors:  Alexander Tschulakow; Sarah Christner; Sylvie Julien; Maximilian Ludinsky; Markus van der Giet; Ulrich Schraermeyer
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

9.  Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration.

Authors:  Mariko Kano; Tetsuju Sekiryu; Yukinori Sugano; Yasuharu Oguchi; Akira Ojima; Kanako Itagaki; Masaaki Saito
Journal:  Clin Ophthalmol       Date:  2015-11-03

10.  Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Authors:  Magda Gharbiya; Ludovico Iannetti; Francesco Parisi; Umberto De Vico; Maria Laura Mungo; Marco Marenco
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.